Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5278-5288

  Donalisio, Manuela ^a   Rusnati, Marco ^b   Cagno, Valeria ^a   Civra, Andrea ^a   Bugatti, Antonella ^b   Giuliani, Andrea ^c   Pirri, Giovanna ^c   Volante, Marco ^a   Papotti, Mauro ^a   Landolfo, Santo ^a   Lembo, David ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Spider Biotech Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DENDRIMER; DIMER; PROTEIN; PROTEOHEPARAN SULFATE; SB007 PYRE PROTEIN; SB056 DIM5 PROTEIN; SB105 A10; SB105 A10 PROTEIN; SB105 PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CELL SURFACE; EPITHELIUM CELL; HEP 2 CELL; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS INFECTIVITY;

ANTIVIRAL AGENTS; CELL LINE; DENDRIMERS; HEPARITIN SULFATE; HUMANS; PEPTIDES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84866328069     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00771-12     Document Type: Article

References (55)

1. Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446:1030-1037. (Pubitemid 46676065)
2. Boas U, Heegaard PM. 2004. Dendrimers in drug research. Chem. Soc. Rev. 33:43-63. (Pubitemid 38376610)
3. Bourgeois C, Bour JB, Lidholt K, Gauthray C, Pothier P. 1998. Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J. Virol. 72:7221-7227. (Pubitemid 28377851)
4. Castilow EM, Varga SM. 2008. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 3:445-454.
5. Cloninger MJ. 2002. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6:742-748. (Pubitemid 35449332)
6. Collins PL, Crowe Jr, JE. 2007. Respiratory syncytial virus and Metapneumovirus. p 1601-1646. In Knipe DM, Howley PM (ed) Fields virology, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
7. Coltrini D, et al. 1993. Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur. J. Biochem. 214:51-58. (Pubitemid 23168517)
8. Corsello G. 2007. Bronchiolitis: the new American Academy of Pediatrics guidelines. J. Chemother. 19:12-14.
9. Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA. 2007. Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J. Virol. 81:261-271. (Pubitemid 44975166)
10. Donalisio M, et al. 2010. Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob. Agents Chemother. 54:4290-4299.
11. Empey KM, Peebles RS, Kolls JK. 2010. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50:1258-1267.
12. Ernst S, Langer R, Cooney CL, Sasisekharan R. 1995. Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30:387-444.
13. Escribano-Romero E, Rawling J, García-Barreno B, Melero JA. 2004. The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans. J. Virol. 78:3524-3532. (Pubitemid 38568294)
14. Falsey AR, et al. 2006. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173:639-643. (Pubitemid 43363805)
15. Feldman SA, Audet S, Beeler JA. 2000. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Virol. 74:6442-6447. (Pubitemid 30429811)
16. Feldman SA, Hendry RM, Beeler JA. 1999. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J. Virol. 73:6610-6617. (Pubitemid 29327843)
17. Gias E, Nielsen SU, Morgan LAF, Toms GL. 2008. Purification of human respiratory syncytial virus by ultracentrifugation in iodixanol density gradient. J. Virol. Methods 147:328-332.
18. Hall CB, et al. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588-598.
19. Hallak LK, Collins PL, Knudson W, Peeples ME. 2000. Iduronic acidcontaining glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:264-275. (Pubitemid 30461305)
20. Hallak LK, Spillmann D, Collins PL, Peeples ME. 2000. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 74:10508-10513.
21. Harris J, Werling D. 2003. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell. Microbiol. 5:671-680. (Pubitemid 37185044)
22. Hsiung GD. 1994. Virus assay, neutralization test, and antiviral assay, p. 46. In Chan VF (ed), Hsiung's diagnostic virology. Yale University Press, New Haven, CT.
23. Johnson S, et al. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224. (Pubitemid 27460986)
24. Karger A, Schmidt U, Buchholz UJ. 2001. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J. Gen. Virol. 82:631-640. (Pubitemid 32177907)
25. Kimura K, et al. 2004. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res. 61:165-171. (Pubitemid 38183056)
26. Krusat T, Strecker HJ. 1997. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch. Virol. 142:1247-1254. (Pubitemid 27266514)
27. Leader S, Kohlhase K. 2002. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr. Infect. Dis. J. 21:629-632. (Pubitemid 34761442)
28. Luganini A, et al. 2010. Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res. 85:532-540.
29. Luganini A, et al. 2011. Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers. Antimicrob. Agents Chemother. 55:3231-3239.
30. Magro M, Andreu D, Gòmez-Puertas P, Melero JA, Palomo C. 2010. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J. Virol. 84:7970-7982.
31. Martínez I, Melero JA. 2000. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J. Gen. Virol. 81:2715-2722.
32. Meissner HC, Rennels MB, Pickering LK, Hall CB. 2004. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab. Pediatr. Infect. Dis. J. 23:284-285. (Pubitemid 38332669)
33. Meyer-Hoffert U, et al. 2008. Identification of heparin/heparan sulfate interacting protein as a major broad-spectrum antimicrobial protein in lung and small intestine. FASEB J. 22:2427-2434. (Pubitemid 351948660)
34. Moscatelli D. 1987. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J. Cell. Physiol. 131:123-130. (Pubitemid 17067272)
35. Pelletier AJ, Mansbach JM, Camargo Jr, CA. 2006. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 118:2418-2423. (Pubitemid 46397582)
36. Perrimon N, Bernfield M. 2000. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404:725-728. (Pubitemid 30212391)
37. Rusnati M, Presta M. 1996. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int. J. Clin. Lab. Res. 26:15-23.
38. Rusnati M, Urbinati C, Presta M. 1993. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. J. Cell. Physiol. 154:152-161. (Pubitemid 23024006)
39. Rusnati M, Urbinati C. 2009. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr. Pharm. Des. 15:2946-2957.
40. Rusnati M, et al. 2009. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicide. Pharmacol. Ther. 123:310-322.
41. Safaiyan F, et al. 1999. Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J. Biol. Chem. 274:36267-36273.
42. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. 2001. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 183:16-22. (Pubitemid 32043037)
43. Shukla D, Spear PG. 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest. 108:503-510. (Pubitemid 32777727)
44. Stewart DL. 2010. Studies recommending palivizumab restriction have serious deficiencies. J. Manag. Care Pharm. 16:509-511.
45. Storey S. 2010. Respiratory syncytial virus market. Nat. Rev. Drug Discov. 9:15-16.
46. Tayyari F, et al. 2011. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17:1132-1135.
47. Techaarpornkul S, Collins PL, Peeples ME. 2002. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294:296-304. (Pubitemid 34920528)
48. Tumova S, Woods A, Couchman JR. 2000. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int. J. Biochem. Cell Biol. 32:269-288. (Pubitemid 30069970)
49. Urbinati C, Chiodelli P, Rusnati M. 2008. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 13:2758-2785.
50. Weisman LE. 2009. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. Cardiovasc. Hematol. Agents Med. Chem. 7:223-233.
51. Welliver RC. 2010. Pharmacotherapy of respiratory syncytial virus infection. Curr. Opin. Pharmacol. 10:289-293.
52. Witvrouw M, De Clercq E. 1997. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen. Pharmacol. 29:497-511. (Pubitemid 27421412)
53. World Health Organization. 2009. Initiative for vaccine research (IVR). Acute Respiratory Infections. Geneva, Switzerland. http://www.who.int/vaccine- research/diseases/ari/en/.
54. Wu P, et al. 2008. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am. J. Respir. Crit. Care Med. 178:1123-1129.
55. Wu H, Pfarr DS, Losonsky GA, Kiener PA. 2008. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr. Top. Microbiol. Immunol. 317:103-123.